Bioventus Inc. (NASDAQ:BVS) Given Average Recommendation of “Buy” by Brokerages

Bioventus Inc. (NASDAQ:BVS) has been given a consensus recommendation of “Buy” by the six research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $14.75.

Several equities research analysts have commented on the stock. CJS Securities started coverage on shares of Bioventus in a report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective on the stock. Barrington Research reiterated an “outperform” rating and issued a $14.00 target price on shares of Bioventus in a research note on Tuesday, June 30th. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research report on Tuesday, June 16th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd.

Bioventus Stock Performance

NASDAQ:BVS opened at $12.06 on Wednesday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13. The business has a fifty day simple moving average of $9.88 and a two-hundred day simple moving average of $9.15. Bioventus has a 1 year low of $5.81 and a 1 year high of $12.53. The company has a market capitalization of $1.01 billion, a P/E ratio of 29.41, a P/E/G ratio of 1.54 and a beta of 0.65.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The firm had revenue of $132.09 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, analysts expect that Bioventus will post 0.79 earnings per share for the current year.

Institutional Trading of Bioventus

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Hillsdale Investment Management Inc. raised its holdings in shares of Bioventus by 148.7% in the 1st quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after acquiring an additional 401,230 shares in the last quarter. Wesbanco Bank Inc. bought a new stake in Bioventus during the first quarter valued at approximately $895,000. Legato Capital Management LLC lifted its position in Bioventus by 1,042.8% during the fourth quarter. Legato Capital Management LLC now owns 137,562 shares of the company’s stock valued at $1,023,000 after purchasing an additional 125,525 shares during the last quarter. Inspire Investing LLC purchased a new position in Bioventus in the 1st quarter worth approximately $1,670,000. Finally, Anderson Financial Strategies LLC grew its stake in Bioventus by 58.3% in the 4th quarter. Anderson Financial Strategies LLC now owns 213,208 shares of the company’s stock worth $1,586,000 after buying an additional 78,488 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.